Skip to content
Medical Health Aged Care

New Alzheimer’s disease blood test shown to work on widely available pathology equipment

The Florey 2 mins read

Diagnostic blood test for Alzheimer's disease another step closer 

Florey researchers – with Australian research volunteers - have evaluated a new diagnostic blood test for Alzheimer’s and found it to be a reliable measure of the disease’s presence and stage. 

Plasma pTau217 blood tests have already been shown to accurately detect Alzheimer’s disease, but aren’t yet available in a clinical setting.  

In research published in eBioMedicine, Florey researchers assessed the test’s performance on the Lumipulse-G® platform which is already in widespread clinical use globally, though is not yet approved for pTau217 tests. 

Lumipulse-G® Plasma pTau217 belongs to Japanese diagnostic company Fujirebio, which expects it to be the first commercially-available blood-based in-vitro diagnostic for patients being assessed for Alzheimer’s disease in the US. 

The study’s senior author Professor Christopher Rowe – clinical lead of The Florey’s Dementia Mission, and Director of Molecular Imaging Research at Austin Health - said the test proved ‘highly reliable’ in the Lumipulse equipment. 

“We compared patients’ blood test results with a PET scan and found that plasma pTau217 not only confirms whether somebody has Alzheimer’s disease, but whether they are at intermediate or advanced stage versus earlier stages,” Professor Rowe said.  

Co-first author Azadeh Feizpour said: “With a new generation of drugs emerging to treat Alzheimer’s disease, detecting a person’s stage of disease is going to be important.”  

The results were based on patient samples and PET scans provided to the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL) and the Australian Dementia Network (ADNeT).  

The findings mean that patients are one step closer to a widely available, low-cost test for earlier and accurate diagnosis of Alzheimer’s disease at a time when treatments for early Alzheimer's Disease are emerging.


About us:

Notes to editor  

Fujirebio performed the test at no charge for the Florey team but were not involved in the analysis of the test. 

Access in clinical practice still requires TGA registration that may be another 1-2 years away. Medicare payment for this test may take another 1-2 years beyond that. 

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to promote brain health and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere. 

Find out more about us on our website: www.florey.edu.au  

Media

More from this category

  • Government Federal, Medical Health Aged Care
  • 01/11/2024
  • 12:22
Catholic Health Australia

Private hospital financial review confirms serious viability issues

Catholic Health Australia (CHA) welcomes the federal government’s report on the Private Hospital Sector Financial Viability Health Check released today, which confirms the sector is facing serious viability issues. “This report confirms what we have been saying for a long time — that the private health sector is under severe and unprecedented funding pressure, especially in mental health and maternity care,” said Catholic Health Australia Director of Health Policy Dr Katharine Bassett. “We thank the government for undertaking this important review and committing to swiftly identifying both short-term and long-term solutions. “We look forward to working with all sector stakeholders,…

  • Medical Health Aged Care, Research Development
  • 01/11/2024
  • 10:19
National Rural Health Alliance

National Rural Health Month: time to spotlight rural health

A time to celebrate and a time for action! November is National Rural Health Month and it’s time to spotlight rural communities and health…

  • Contains:
  • Education Training, Medical Health Aged Care
  • 01/11/2024
  • 00:01
UNSW Sydney

Record donation awarded to UNSW Sydney will enable the Kirby Institute and partners to advance cervical cancer elimination in the Pacific

Media Release 01.00AM AEDT, Friday 1 November 2024 Record donation awarded to UNSW Sydney will enable the Kirby Institute and partners to advance cervical cancer elimination in the Pacific A $25.9 million donation from the Swire Group will support cervical cancer screening and treatment for over 130,000 women in seven Pacific countries.   UNSW Sydney has received the largest single philanthropic donation in its history to work with regional partners to tackle one of the deadliest preventable cancers in the Pacific. The $25.9 million donation from the Swire Group will enable UNSW’s Kirby Institute to work with partners in Australia…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.